Full Length Research Paper
References
Banach M, Patti AM, Giglio RV, Cicero AFG, Bajraktari G, Brucker E, Descamps O, Djuric D, Ezhov M, Fras Z, von Haehling S (2018). The role of nutraceuticals in statin intolerant patients. Journal of the America College of Cardiology 72(1):96-118 |
|
Food and Drug Administration (FDA) (2016). Labeling and Nutrition. Food and Drug Administration, US Department of Health and Human Services. 5 October 2016. Retrieved 21 Nov 2020 |
|
Gupta S, Yadav AK (2022). Emerging trend of chondroitin sulfate in nanoparticles preparation, targeting, and pharmaceutical applications. Polysaccharide Nanoparticles pp. 65-90. |
|
Kaplan S (2019). Supplement makers touting cures for Alzheimer's and other diseases get FDA warning. New York Times, 11 February 2019. Retrieved 21 Nov 2020 |
|
Lockwood GB (2015). Quality evaluation and safety of commercially available nutraceutical and formulated products. In: Nutraceutical and Functional Processing Technology (pp. 113-150). |
|
Melia CD, Davis SS (1989). Mechanisms of drug release from tablets and capsules. I: disintegration. Alimentary Pharmacology and Therapeutics 3(3):223-232. |
|
Rawat S, Derle DV, Fukte SR, Shinde PR, Parve BS (2014). Superdisintegrants: an overview. World Journal of Pharmacy and Pharmaceutical Sciences 3(5):263-278. |
|
Russell AS, Aghazadeh-Habash, A, Jamali F (2002). Active ingredient consistency of commercially available glucosamine sulfate products. The Journal of Rheumatology 29(11):2407-2409. |
|
Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH (2016). Adjunctive nutraceuticals for depression: A systematic review and meta-nalysis. American Journal of Psychiatry 173(6):575-587. |
|
Verma K, Sharma PK, Dudhe R, Patro ASK (2014). Formulation, design and development of Mifepristone immediate release tablet. International Journal of Pharma Sciences and Research 5(11):760-769. |
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0